Journal article

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial

A Keech, P Mitchell, P Summanen, J O'Day, T Davis, M Moffitt, MR Taskinen, R Simes, D Tse, E Williamson, A Merrifield, L Laatikainen, M d'Emden, D Crimet, R O'Connell, P Colman

Lancet | ELSEVIER SCIENCE INC | Published : 2007

Abstract

Background: Laser treatment for diabetic retinopathy is often associated with visual field reduction and other ocular side-effects. Our aim was to assess whether long-term lipid-lowering therapy with fenofibrate could reduce the progression of retinopathy and the need for laser treatment in patients with type 2 diabetes mellitus. Methods: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study was a multinational randomised trial of 9795 patients aged 50-75 years with type 2 diabetes mellitus. Eligible patients were randomly assigned to receive fenofibrate 200 mg/day (n=4895) or matching placebo (n=4900). At each clinic visit, information concerning laser treatment for diab..

View full abstract

University of Melbourne Researchers